PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 131 filers reported holding PROGENICS PHARMACEUTICALS IN in Q1 2020. The put-call ratio across all filers is 0.49 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $100,000 | -24.8% | 26,200 | 0.0% | 0.00% | -25.0% |
| Q4 2019 | $133,000 | +3.9% | 26,200 | +3.6% | 0.00% | -20.0% |
| Q3 2019 | $128,000 | -17.9% | 25,290 | 0.0% | 0.01% | -54.5% |
| Q2 2019 | $156,000 | +35.7% | 25,290 | +2.1% | 0.01% | +37.5% |
| Q1 2019 | $115,000 | +12.7% | 24,780 | +2.2% | 0.01% | +33.3% |
| Q4 2018 | $102,000 | -38.9% | 24,250 | +16.7% | 0.01% | -33.3% |
| Q2 2018 | $167,000 | -20.1% | 20,780 | -26.0% | 0.01% | -10.0% |
| Q1 2018 | $209,000 | +33.1% | 28,070 | +6.5% | 0.01% | +25.0% |
| Q4 2017 | $157,000 | -19.1% | 26,350 | 0.0% | 0.01% | -20.0% |
| Q3 2017 | $194,000 | +71.7% | 26,350 | +58.7% | 0.01% | +66.7% |
| Q2 2017 | $113,000 | -25.2% | 16,600 | +4.0% | 0.01% | -14.3% |
| Q1 2017 | $151,000 | – | 15,960 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Phocas Financial Corp. | 1,033,328 | $6,376,000 | 0.68% |
| ARDSLEY ADVISORY PARTNERS LP | 650,000 | $4,011,000 | 0.63% |
| Worth Venture Partners, LLC | 138,357 | $853,000 | 0.47% |
| RICE HALL JAMES & ASSOCIATES, LLC | 2,242,503 | $13,836,000 | 0.46% |
| HIGHLAND CAPITAL MANAGEMENT LP | 716,880 | $4,423,000 | 0.26% |
| FARALLON CAPITAL MANAGEMENT LLC | 5,543,386 | $34,203,000 | 0.22% |
| Point72 Asset Management, L.P. | 5,858,749 | $36,148,000 | 0.19% |
| PINNACLE ASSOCIATES LTD | 1,298,723 | $8,013,000 | 0.19% |
| Fosun International Ltd | 472,580 | $2,750,000 | 0.18% |
| J. Goldman & Co LP | 400,000 | $2,468,000 | 0.17% |